Marginal Lymphoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma (NCT00085696) | Millennium Pharmaceuticals, Inc. | 2004-05-01 |
Track Marginal Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.